Clinical trial
Prospective Validation Trial of Taxane Therapy (Docetaxel or Weekly Paclitaxel) and Risk of Chemotherapy-Induced Peripheral Neuropathy in African American Women
NCT04001829 is registered in ClinicalTrials.gov with ECOG-ACRIN Cancer Research Group as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Prospective Validation Trial of Taxane Therapy (Docetaxel or Weekly Paclitaxel) and Risk of Chemotherapy-Induced Peripheral Neuropathy in African American Women
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- August 9, 2019
- Completion date
- April 5, 2027
- Enrollment
- 249 (actual)
- Sites
- 482
Conditions
As the registry lists them; a condition with its own page is linked.
anatomic stage i breast cancer ajcc v8, anatomic stage ia breast cancer ajcc v8, anatomic stage ib breast cancer ajcc v8, anatomic stage ii breast cancer ajcc v8, anatomic stage iia breast cancer ajcc v8, anatomic stage iib breast cancer ajcc v8, anatomic stage iii breast cancer ajcc v8, anatomic stage iiia breast cancer ajcc v8, anatomic stage iiib breast cancer ajcc v8, anatomic stage iiic breast cancer ajcc v8, invasive breast carcinoma, prognostic stage i breast cancer ajcc v8, prognostic stage ia breast cancer ajcc v8, prognostic stage ib breast cancer ajcc v8, prognostic stage ii breast cancer ajcc v8, prognostic stage iia breast cancer ajcc v8, prognostic stage iib breast cancer ajcc v8, prognostic stage iii breast cancer ajcc v8, prognostic stage iiia breast cancer ajcc v8, prognostic stage iiib breast cancer ajcc v8, prognostic stage iiic breast cancer ajcc v8